Cediranib/AZD2171 Inhibits Bone and Brain Metastasis in a Preclinical Model of Advanced Prostate Cancer

被引:42
|
作者
Yin, Juan Juan
Zhang, Luhua
Munasinghe, Jeeva [2 ]
Linnoila, R. Ilona
Kelly, Kathleen [1 ]
机构
[1] NCI, Cell & Canc Biol Branch, Ctr Canc Res, Bethesda, MD 20892 USA
[2] Natl Inst Neurol Disorders & Stroke, Lab Funct & Mol Imaging & Mouse Imaging Facil, NIH, Bethesda, MD USA
关键词
TYROSINE KINASE INHIBITOR; ANTIANGIOGENIC THERAPY; TUMOR VASCULATURE; VEGF INHIBITORS; CELLS; GROWTH; ANGIOGENESIS; PROGRESSION; MECHANISMS; PROMOTES;
D O I
10.1158/0008-5472.CAN-10-1435
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Late stage or aggressive cancers exhibit metastatic growth at multiple sites, and the characterization of treatment response in various organs to drugs with potentially wide-ranging efficacy is needed. Tumor cells that induce angiogenesis are a common characteristic of metastatic disease, and clinically, antiangiogenic therapies have shown value in the setting of advanced cancer. However, recent preclinical studies have suggested that exposure to antiangiogenic drugs can increase tumor invasiveness and metastasis, making it important to determine which contexts antiangiogenic therapy is most appropriate. We describe here the effects of cediranib, a receptor tyrosine kinase inhibitor, in a model of advanced prostate cancer metastatic to skeleton and brain. Treatment with cediranib decreased metastatic tumor burden in the brain and bone, decreased cerebral vasogenic edema, and improved survival, despite increasing the invasive histology of brain metastases. Short-duration cediranib treatment given at the time of tumor cell dissemination was sufficient to inhibit the establishment and subsequent growth of bone metastases, although brain metastases were subject to rebound growth after the discontinuation of cediranib. Distinct growth patterns at different organ sites in the same animal showed that certain tumor microenvironments such as bone may be most amenable to interventions by anti-vascular endothelial growth factor (VEGF) therapies. In addition, anti-VEGF treatment may be of utility in decreasing the rapid growth of solid brain metastases and vasogenic edema in patients with advanced cancer, leading to reduced morbidity and associated clinical benefit. Cancer Res; 70(21); 8662-73. (C)2010 AACR.
引用
收藏
页码:8662 / 8673
页数:12
相关论文
共 50 条
  • [41] Phase I clinical trial evaluating the safety, pharmacokinetics and biological effect of intravenous bevacizumab (avastin) in combination with escalating doses of AZD2171 (cediranib) administered orally for 21 consecutive days to patients with advanced malignancies (NCI protocol #7534)
    Hong, David S.
    Davis, Darrin
    Naing, Aung
    Fu, Siqing
    Falchook, Gerald
    Ricks, Linda W.
    Bekele, Nebe
    Mittleman, David
    Liu, W.
    Ivy, Percy
    Herbst, Roy
    Kurzrock, Razelle
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [42] Cathepsin L inactivation leads to multimodal inhibition of prostate cancer cell dissemination in a preclinical bone metastasis model
    Sudhan, Dhivya R.
    Pampo, Christine
    Rice, Lori
    Siemann, Dietmar W.
    INTERNATIONAL JOURNAL OF CANCER, 2016, 138 (11) : 2665 - 2677
  • [43] TREATMENT WITH INTERLEUKIN 6 RECEPTOR ANTIBODIES INHIBITS PROSTATE CANCER GROWTH IN A MURINE MODEL OF BONE METASTASIS
    Basel, D.
    Zheng, Y.
    Kelly, J.
    Buttgereit, F.
    Sutherland, R. L.
    Dunstan, C. R.
    Zhou, H.
    Seibel, M. J.
    OSTEOPOROSIS INTERNATIONAL, 2011, 22 : S534 - S535
  • [44] Optimization and Characterization of a Bone Culture Model to Prostate Cancer Bone Metastasis
    Wu, Yi-Hsuan
    Gugala, Zbigniew
    Barry, Megan M.
    Shen, Yichao
    Dasgupta, Subhamoy
    Wang, Hai
    MOLECULAR CANCER THERAPEUTICS, 2022, 21 (08) : 1360 - 1368
  • [45] The dialyzable leukocyte extract Transferon™ inhibits tumor growth and brain metastasis in a murine model of prostate cancer
    Hernandez-Esquivel, Miguel A.
    Perez-Torres, Armando
    Romero-Romero, Laura
    Reyes-Matute, Alonso
    Loaiza, Brenda
    Mellado-Sanchez, Gabriela
    Pavon, Lenin
    Medina-Rivero, Emilio
    Pestell, Richard G.
    Perez-Tapia, Sonia M.
    Velasco-Velazquez, Marco A.
    BIOMEDICINE & PHARMACOTHERAPY, 2018, 101 : 938 - 944
  • [46] Effects of AZD2171 on pharmacokinetics (PK) of carboplatin (C) and paclitaxel (P) in patients with advanced non-small cell lung cancer (NSCLC): a study of the National Cancer Institute of Canada Clinical Trials Group
    Chen, E.
    Zhang, W.
    Lauri, S.
    Arnold, A.
    Gauthier, I.
    Goss, G.
    Ellis, P.
    Shepherd, F.
    Mathews, S.
    Seymour, L.
    EJC SUPPLEMENTS, 2006, 4 (12): : 32 - 32
  • [47] Reproducible preclinical models of androgen receptor driven human prostate cancer bone metastasis
    Yin, JuanJuan
    Daryanani, Asha
    Lu, Fan
    Ku, Anson T.
    Bright, John R.
    Alilin, Aian Neil S.
    Bowman, Joel
    Lake, Ross
    Li, Chennan
    Truong, Tri M.
    Twohig, Joseph D.
    Mostaghel, Elahe A.
    Ishikawa, Masaki
    Simpson, Mark
    Trostel, Shana Y.
    Corey, Eva
    Sowalsky, Adam G.
    Kelly, Kathleen
    PROSTATE, 2024, 84 (11): : 1033 - 1046
  • [48] Continuous load bearing exercise inhibits the development of prostate cancer bone metastasis
    Wang, Ning
    Arredondo, Hector M.
    Sprules, Alexandria R.
    Eaton, Colby L.
    CANCER RESEARCH, 2020, 80 (16)
  • [49] Procoxacin bidirectionally inhibits osteoblastic and osteoclastic activity in bone and suppresses bone metastasis of prostate cancer
    Depei Kong
    Chen Ye
    Chenxi Zhang
    Xiaochen Sun
    Fubo Wang
    Rui Chen
    Guangan Xiao
    Shipeng He
    Jianrong Xu
    Xiwu Rao
    Jianzhong Ai
    Xu Gao
    Hong Li
    Li Su
    Journal of Experimental & Clinical Cancer Research, 42
  • [50] Targeting of αv integrins in prostate cancer and bone stroma inhibits bone metastasis formation and progression
    van der Horst, Geertje
    van den Hoogen, Christel
    Buijs, Jeroen
    Cheung, Henry
    Feyen, Jean
    Pujuguet, Philippe
    Pelger, Rob
    Heckmann, Bertrand
    Clement-Lacroix, Philippe
    van der Pluijm, Gabri
    CANCER TREATMENT REVIEWS, 2008, 34 : S76 - S77